Please use this identifier to cite or link to this item:
PIRA download icon_1.1View/Download Full Text
Title: Optical treatment of amblyopia in older children and adults is essential prior to enrolment in a clinical trial
Authors: Gao, TY
Anstice, N
Babu, RJ
Black, JM
Bobier, WR
Dai, S
Guo, CX
Hess, RF
Jenkins, M
Jiang, Y
Kearns, L
Kowal, L
Lam, CSY 
Pang, PCK 
Parag, V
South, J
Staffieri, SE
Wadham, A
Walker, N
Thompson, B
Issue Date: Mar-2018
Source: Ophthalmic and physiological optics, Mar. 2018, v. 38, no. 2, p. 129-143
Abstract: Purpose: Optical treatment alone can improve visual acuity (VA) in children with amblyopia, thus clinical trials investigating additional amblyopia therapies (such as patching or videogames) for children require a preceding optical treatment phase. Emerging therapies for adult patients are entering clinical trials. It is unknown whether optical treatment is effective for adults with amblyopia and whether an optical correction phase is required for trials involving adults.
Methods: We examined participants who underwent optical treatment in the Binocular Treatment for Amblyopia using Videogames (BRAVO) clinical trial (ANZCTR ID: ACTRN12613001004752). Participants were recruited in three age groups (7 to 12, 13 to 17, or ≥18 years), and had unilateral amblyopia due to anisometropia and/or strabismus, with amblyopic eye VA of 0.30–1.00 logMAR (6/12 to 6/60, 20/40 to 20/200). Corrective lenses were prescribed based on cycloplegic refraction to fully correct any anisometropia. VA was assessed using the electronic visual acuity testing algorithm (e-ETDRS) test and near stereoacuity was assessed using the Randot Preschool Test. Participants were assessed every four weeks up to 16 weeks, until either VA was stable or until amblyopic eye VA improved to better than 0.30 logMAR, rendering the participant ineligible for the trial.
Results: Eighty participants (mean age 24.6 years, range 7.6–55.5 years) completed four to 16 weeks of optical treatment. A small but statistically significant mean improvement in amblyopic eye VA of 0.05 logMAR was observed (S.D. 0.08 logMAR; paired t-test p < 0.0001). Twenty-five participants (31%) improved by ≥1 logMAR line and of these, seven (9%) improved by ≥2 logMAR lines. Stereoacuity improved in 15 participants (19%). Visual improvements were not associated with age, presence of strabismus, or prior occlusion treatment. Two adult participants withdrew due to intolerance to anisometropic correction. Sixteen out of 80 participants (20%) achieved better than 0.30 logMAR VA in the amblyopic eye after optical treatment. Nine of these participants attended additional follow-up and four (44%) showed further VA improvements.
Conclusions: Improvements from optical treatment resulted in one-fifth of participants becoming ineligible for the main clinical trial. Studies investigating additional amblyopia therapies must include an appropriate optical treatment only phase and/or parallel treatment group regardless of patient age. Optical treatment of amblyopia in adult patients warrants further investigation.
Keywords: Adults
Optical treatment
Refractive adaptation
Publisher: Wiley-Blackwell
Journal: Ophthalmic and physiological optics 
ISSN: 0275-5408
EISSN: 1475-1313
DOI: 10.1111/opo.12437
Description: Tina Y. Gao,Nicola Anstice,Raiju J. Babu,Joanna M. Black,William R. Bobier,Shuan Dai,Cindy X. Guo,Robert F. Hess,Michelle Jenkins,Yannan Jiang,Lisa Kearns,Lionel Kowal,Carly S. Y. Lam,Peter C. K. Pang,Varsha Parag,Jayshree South,Sandra Elfride Staffieri,Angela Wadham,Natalie Walker,Benjamin Thompson,on behalf of the Binocular Treatment of Amblyopia Using Videogames (BRAVO) Study Team
Rights: © 2018 The Authors Ophthalmic & Physiological Optics © 2018 The College of Optometrists
This is the peer reviewed version of the following article: Gao, T. Y., Anstice, N., Babu, R. J., Black, J. M., Bobier, W. R., Dai, S., ... & Binocular Treatment of Amblyopia Using Videogames (BRAVO) Study Team. (2018). Optical treatment of amblyopia in older children and adults is essential prior to enrolment in a clinical trial. Ophthalmic and Physiological Optics, 38(2), 129-143, which has been published in final form at This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.
Appears in Collections:Journal/Magazine Article

Files in This Item:
File Description SizeFormat 
Lam_Optical_Treatment_Amblyopia.pdfPre-Published version1.78 MBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
View full-text via PolyU eLinks SFX Query
Show full item record

Page views

Last Week
Last month
Citations as of Jun 4, 2023


Citations as of Jun 4, 2023


Citations as of Jun 2, 2023


Last Week
Last month
Citations as of Jun 1, 2023

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.